4D Molecular Therapeutics (NASDAQ:FDMT) Issues Quarterly Earnings Results

4D Molecular Therapeutics (NASDAQ:FDMT) released its quarterly earnings results on Friday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Performance

FDMT opened at $4.53 on Friday. The stock has a market capitalization of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. The company has a fifty day moving average of $5.22 and a 200 day moving average of $8.64. 4D Molecular Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $36.25.

Analyst Upgrades and Downgrades

FDMT has been the topic of several recent research reports. Chardan Capital decreased their price target on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. Leerink Partners reduced their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Bank of America reduced their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.